58 studies found for:    Mitochondrial Myopathies
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Recruiting RTA 408 Capsules in Patients With Mitochondrial Myopathy - MOTOR
Condition: MItochondrial Myopathies
Interventions: Drug: Omaveloxolone capsules, 2.5 mg;   Drug: omaveloxolone capsules, 5 mg;   Drug: omaveloxolone capsules, 10 mg;   Drug: Placebo capsules;   Drug: omaveloxolone capsules, 20 mg;   Drug: omaveloxolone capsules, TBD mg;   Drug: omaveloxolone capsules, 40 mg;   Drug: omaveloxolone capsules, 80 mg
2 Completed A Study Investigating the Safety, Tolerability, and Efficacy of MTP-131 for the Treatment of Mitochondrial Myopathy
Condition: Mitochondrial Myopathy
Interventions: Drug: MTP-131;   Drug: Placebo
3 Completed Pilot Compassionate Use Study of Thioctic Acid Treatment in Mitochondrial Myopathy
Condition: Mitochondrial Myopathy
Intervention: Drug: thioctic acid
4 Unknown  The Effects of Exercise Versus Inactivity on People With Mitochondrial Muscle Disease
Condition: Mitochondrial Myopathy
Intervention: Behavioral: Exercise
5 Recruiting A Study of Bezafibrate in Mitochondrial Myopathy
Condition: Mitochondrial Diseases
Intervention: Drug: Bezafibrate
6 Completed Defining 31Phosphorous Magnetic Resonance Spectroscopy Characteristics in Patients With Mitochondrial Myopathy
Condition: Mitochondrial Disease
Intervention:
7 Completed Study of the Metabolism of Pyruvate and Related Problems in Patients With Lactic Acidemia
Conditions: Mitochondrial Myopathy;   MELAS Syndrome;   Lactic Acidosis
Intervention:
8 Completed Nutritional Assessment in Mitochondrial Cytopathy
Conditions: Mitochondrial Diseases;   Mitochondrial Myopathies;   Mitochondrial Cytopathies
Intervention:
9 Enrolling by invitation A Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Injections of Elamipretide (MTP-131) in Subjects With Genetically Confirmed Mitochondrial Disease Previously Treated in the Stealth BioTherapeutics SPIMM-201 Study
Condition: Primary Mitochondrial Disease
Interventions: Drug: Elamipretide;   Drug: Placebo
10 Recruiting Study of Inherited Neurological Disorders
Conditions: Ataxia;   Motor Neuron Disease;   Muscular Disease;   Muscular Dystrophy;   Peripheral Nervous System Disease
Intervention:
11 Recruiting Fat and Sugar Metabolism During Exercise in Patients With Metabolic Myopathy
Conditions: Metabolism, Inborn Errors;   Lipid Metabolism, Inborn Errors;   Carbohydrate Metabolism, Inborn Errors;   Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency;   Glycogenin-1 Deficiency (Glycogen Storage Disease Type XV);   Carnitine Palmitoyl Transferase 2 Deficiency;   VLCAD Deficiency;   Medium-chain Acyl-CoA Dehydrogenase Deficiency;   Multiple Acyl-CoA Dehydrogenase Deficiency;   Carnitine Transporter Deficiency;   Neutral Lipid Storage Disease;   Glycogen Storage Disease Type II;   Glycogen Storage Disease Type III;   Glycogen Storage Disease Type IV;   Glycogen Storage Disease Type V;   Muscle Phosphofructokinase Deficiency;   Phosphoglucomutase 1 Deficiency;   Phosphoglycerate Mutase Deficiency;   Phosphoglycerate Kinase Deficiency;   Phosphorylase Kinase Deficiency;   Beta Enolase Deficiency;   Lactate Dehydrogenase Deficiency;   Glycogen Synthase Deficiency
Intervention: Other: Sugar
12 Available Compassionate Use of Triheptanoin (C7) for Fatty Acid Oxidation Disorders and Glycogen Storage Disease
Conditions: Very Long-chain acylCoA Dehydrogenase (VLCAD) Deficiency;   Carnitine Palmitoyltransferase Deficiencies (CPT1, CPT2);   Mitochondrial Trifunctional Protein Deficiency;   Long-chain Hydroxyacyl-CoA Dehydrogenase Deficiency;   Glycogen Storage Disorders;   Pyruvate Carboxylase Deficiency Disease;   ACYL-CoA DEHYDROGENASE FAMILY, MEMBER 9, DEFICIENCY of
Intervention: Drug: triheptanoin
13 Terminated Vitamin E Treatment for Long-Chain 3-Hydroxyacyl Coenzyme A (CoA) Dehydrogenase (LCHAD) Associated Neuropathy
Conditions: Peripheral Neuropathy;   Mitochondrial Trifunctional Protein Deficiency
Intervention: Dietary Supplement: Vitamin E supplement
14 Completed
Has Results
Fatty Acid Oxidation Disorders & Body Weight Regulation Grant
Condition: Trifunctional Protein Deficiency
Intervention:
15 Recruiting Fatty Acid Oxidation Defects and Insulin Sensitivity
Conditions: Very Long-chain Acyl-CoA Dehydrogenase Deficiency;   Trifunctional Protein Deficiency;   Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency;   Medium-chain Acyl-CoA Dehydrogenase Deficiency;   Normal Volunteers
Interventions: Drug: Intralipid/Heparin;   Drug: Glycerol/Saline;   Drug: Hyperinsulinemic euglycemic clamp
16 Completed High Protein Diet in Patients With Long-chain Fatty Acid Oxidation Disorders
Conditions: Very Long-chain Acyl-CoA Dehydrogenase Deficiency;   Trifunctional Protein Deficiency;   Carnitine Palmitoyltransferase 2 Deficiency;   Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency
Intervention: Behavioral: Diet counseling
17 Recruiting Natural History Study - Mitochondrial Disease
Condition: m.3243 A>G Mitochondrial DNA Mutation Carrier or Relative
Intervention:
18 Completed Ketones & Mitochondrial Heteroplasmy
Conditions: MELAS Syndrome;   Mitochondrial Diseases
Intervention: Dietary Supplement: Medium-Chain Triglycerides
19 Completed Effect Of The System In The Enriched Fat Metabolism Of The Child Reached Mitochondrial Cytopathy
Condition: Mitochondrial Cytopathies Disorders
Interventions: Other: high fat diet;   Other: normal fat diet
20 Completed Responses to Influenza Vaccine in Patients With Mitochondrial Disorders (MELAS)
Condition: MELAS Syndrome
Intervention: Biological: Intramuscular seasonal trivalent inactivated influenza vaccine

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years